Vimarsana
Biggest News Aggregation in the World

Page 2 - Inform Diagnostics News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Inform Diagnostics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Inform Diagnostics Today - Breaking & Trending Today

Fulgent Genetics, Inc. (NASDAQ:FLGT) Q1 2023 Earnings Call Transcript - Vimarsana News

Fulgent Genetics, Inc. (NASDAQ:FLGT) Q1 2023 Earnings Call Transcript

Operator: Hello and welcome to the Fulgent Genetics Q1 2023 Earnings Conference Call and Webcast. [Operator Instructions] As a reminder, this conference is being recorded.

Fulgent Genetics, Inc. (NASDAQ:FLGT) Q4 2022 Earnings Call Transcript - Vimarsana News

Fulgent Genetics, Inc. (NASDAQ:FLGT) Q4 2022 Earnings Call Transcript

Operator: Hello and welcome to the Fulgent Genetics Q4 and Fiscal Year 2022 Earnings Conference Call and Webcast. As a reminder, this conference is being recorded.

DOJ Scrutiny Of EHR Vendors Continues With $45 Million Settlement For Alleged Kickbacks And False Claims - Healthcare - Vimarsana News

DOJ Scrutiny Of EHR Vendors Continues With $45 Million Settlement For Alleged Kickbacks And False Claims - Healthcare

On November 1, 2022, the Department of Justice ("DOJ") announced that Florida-based electronic health record ("EHR") vendor, Modernizing Medicine ("ModMed")...

Source: mondaq.com
Modernizing Medicine to pay $45M to resolve False Claims Act allegations - Vimarsana News

Modernizing Medicine to pay $45M to resolve False Claims Act allegations

The U.S. Department of Justice alleges that the EHR vendor accepted and provided "unlawful remuneration in exchange for referrals and by causing its users to report inaccurate information in connection with claims for federal incentive payments."

Fulgent Share Price Tumbles as Covid Test Revenue Tails Off - Los Angeles Business Journal - Vimarsana News

Fulgent Share Price Tumbles as Covid Test Revenue Tails Off - Los Angeles Business Journal

Learn more about Fulgent Genetics’ share price tumbling as Covid test revenue falls and the company’s plans for a post-Covid testing strategy.